

# Pierre-Emmanuel Morange

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6733633/publications.pdf>

Version: 2024-02-01

288  
papers

15,892  
citations

16451

64  
h-index

21540

114  
g-index

323  
all docs

323  
docs citations

323  
times ranked

22561  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. <i>Science</i> , 2020, 370, .	12.6	1,749
2	DNA methylation and body-mass index: a genome-wide analysis. <i>Lancet</i> , The, 2014, 383, 1990-1998.	13.7	686
3	High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2006, 4, 542-549.	3.8	349
4	Benefit of a 600-mg Loading Dose of Clopidogrel on Platelet Reactivity and Clinical Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Undergoing Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2006, 48, 1339-1345.	2.8	329
5	Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity. <i>Diabetes</i> , 2000, 49, 1374-1380.	0.6	322
6	Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5) study. <i>Journal of the American College of Cardiology</i> , 2014, 64, 3070-3078.	2.2	316
7	Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1575-1579.	3.8	315
8	Common susceptibility alleles are unlikely to contribute as strongly as the FV and ABO loci to VTE risk: results from a GWAS approach. <i>Blood</i> , 2009, 113, 5298-5303.	1.4	283
9	Meta-analysis of 65,734 Individuals Identifies TSPAN15 and SLC44A2 as Two Susceptibility Loci for Venous Thromboembolism. <i>American Journal of Human Genetics</i> , 2015, 96, 532-542.	6.2	222
10	Genomic and phenotypic insights from an atlas of genetic effects on DNA methylation. <i>Nature Genetics</i> , 2021, 53, 1311-1321.	21.4	218
11	Human genetic and immunological determinants of critical COVID-19 pneumonia. <i>Nature</i> , 2022, 603, 587-598.	27.8	216
12	Comparison of Omeprazole and Pantoprazole Influence on a High 150-mg Clopidogrel Maintenance Dose. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1149-1153.	2.8	212
13	Endothelial Cell Markers and the Risk of Coronary Heart Disease. <i>Circulation</i> , 2004, 109, 1343-1348.	1.6	203
14	ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 98, 838-843.	3.4	203
15	Effect of Cytochrome P450 Polymorphisms on Platelet Reactivity After Treatment With Clopidogrel in Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2008, 101, 1088-1093.	1.6	194
16	Stromal Cells Are the Main Plasminogen Activator Inhibitor-1-Producing Cells in Human Fat. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 173-178.	2.4	182
17	Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. <i>Diabetes</i> , 1997, 46, 860-867.	0.6	175
18	Activated thrombin activatable fibrinolysis inhibitor levels are associated with the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 49-57.	3.8	169

#	ARTICLE	IF	CITATIONS
19	Plasma PAI-1 Levels Are More Strongly Related to Liver Steatosis Than to Adipose Tissue Accumulation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 1262-1268.	2.4	168
20	Genomic and transcriptomic association studies identify 16 novel susceptibility loci for venous thromboembolism. <i>Blood</i> , 2019, 134, 1645-1657.	1.4	162
21	Apolipoprotein(a) Genetic Sequence Variants Associated With Systemic Atherosclerosis and Coronary Atherosclerotic Burden But Not With Venous Thromboembolism. <i>Journal of the American College of Cardiology</i> , 2012, 60, 722-729.	2.8	149
22	Maximizing the Power of Principal-Component Analysis of Correlated Phenotypes in Genome-wide Association Studies. <i>American Journal of Human Genetics</i> , 2014, 94, 662-676.	6.2	149
23	Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. <i>Blood</i> , 2001, 97, 2053-2058.	1.4	140
24	Glycoprotein IIb/IIIa Inhibitors Improve Outcome After Coronary Stenting in Clopidogrel Nonresponders. <i>JACC: Cardiovascular Interventions</i> , 2008, 1, 649-653.	2.9	140
25	Plasma Thrombin-Activatable Fibrinolysis Inhibitor Antigen Concentration and Genotype in Relation to Myocardial Infarction in the North and South of Europe. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002, 22, 867-873.	2.4	137
26	Low-grade inflammation may play a role in the etiology of the metabolic syndrome in patients with coronary heart disease: the HIFMECH study. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 852-857.	3.4	137
27	The Poly(ADP-ribose) Polymerase PARP-1 Is Required for Oxidative Stress-induced TRPM2 Activation in Lymphocytes. <i>Journal of Biological Chemistry</i> , 2008, 283, 24571-24583.	3.4	131
28	Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease. <i>Circulation</i> , 2013, 128, 1310-1324.	1.6	128
29	Genetics of Venous Thrombosis: Insights from a New Genome Wide Association Study. <i>PLoS ONE</i> , 2011, 6, e25581.	2.5	127
30	Influence of PAI-1 on Adipose Tissue Growth and Metabolic Parameters in a Murine Model of Diet-Induced Obesity. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1150-1154.	2.4	124
31	Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. <i>EuroIntervention</i> , 2009, 5, 325-329.	3.2	123
32	Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology. <i>Thrombosis and Haemostasis</i> , 2013, 110, 669-680.	3.4	121
33	Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. <i>Biguanides and the Prevention of the Risk of Obesity. Diabetes Care</i> , 1998, 21, 1967-1972.	8.6	120
34	Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. <i>Diabetes</i> , 1999, 48, 890-895.	0.6	117
35	Human CalDAG-GEFI gene ( <i>RASGRP2</i> ) mutation affects platelet function and causes severe bleeding. <i>Journal of Experimental Medicine</i> , 2014, 211, 1349-1362.	8.5	117
36	Long-range epigenetic regulation is conferred by genetic variation located at thousands of independent loci. <i>Nature Communications</i> , 2015, 6, 6326.	12.8	115

#	ARTICLE	IF	CITATIONS
37	Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. <i>Blood</i> , 2006, 108, 1492-1496.	1.4	103
38	High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. <i>Thrombosis and Haemostasis</i> , 2007, 97, 282-287.	3.4	102
39	Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. <i>Circulation</i> , 2019, 139, 620-635.	1.6	102
40	PAI-1 Produced Ex Vivo by Human Adipose Tissue Is Relevant to PAI-1 Blood Level. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 1361-1365.	2.4	99
41	Plasma TAFI Antigen Variations in Healthy Subjects. <i>Thrombosis and Haemostasis</i> , 2000, 83, 902-905.	3.4	99
42	A Genome-Wide Association Study for Venous Thromboembolism: The Extended Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. <i>Genetic Epidemiology</i> , 2013, 37, 512-521.	1.3	99
43	Genetic Polymorphisms and Coronary Artery Disease in the South of France. <i>Thrombosis and Haemostasis</i> , 2000, 83, 212-216.	3.4	98
44	Haemostatic Factors and the Risk of Cardiovascular Death in Patients With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 2793-2799.	2.4	96
45	C-Reactive Protein, Interleukin 6, Fibrinogen and Risk of Sudden Death in European Middle-Aged Men: The PRIME Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010, 30, 2047-2052.	2.4	96
46	CYP2C19*2 and *17 Alleles Have a Significant Impact on Platelet Response and Bleeding Risk in Patients Treated With Prasugrel After Acute Coronary Syndrome. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1280-1287.	2.9	92
47	Nutritionally Induced Obesity Is Attenuated in Transgenic Mice Overexpressing Plasminogen Activator Inhibitor-1. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2003, 23, 78-84.	2.4	91
48	Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. <i>Blood</i> , 2012, 120, 4873-4881.	1.4	90
49	Recommendations on Testing for Thrombophilia in Venous Thromboembolic Disease: a French Consensus Guideline. <i>Journal Des Maladies Vasculaires</i> , 2009, 34, 156-203.	0.6	89
50	Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. <i>International Journal of Obesity</i> , 2012, 36, 422-430.	3.4	89
51	Exclusive expression of transmembrane TNF- $\alpha$ in mice reduces the inflammatory response in early lipid lesions of aortic sinus. <i>Atherosclerosis</i> , 2004, 172, 211-218.	0.8	87
52	Thrombin-Activatable Fibrinolysis Inhibitor Antigen Levels and Cardiovascular Risk Factors. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 2156-2161.	2.4	86
53	Genetic Associations for Activated Partial Thromboplastin Time and Prothrombin Time, their Gene Expression Profiles, and Risk of Coronary Artery Disease. <i>American Journal of Human Genetics</i> , 2012, 91, 152-162.	6.2	85
54	Associations of autozygosity with a broad range of human phenotypes. <i>Nature Communications</i> , 2019, 10, 4957.	12.8	84

#	ARTICLE	IF	CITATIONS
55	Genetics of Venous Thrombosis: update in 2015. <i>Thrombosis and Haemostasis</i> , 2015, 114, 910-919.	3.4	81
56	A Granulocytic Signature Identifies COVID-19 and Its Severity. <i>Journal of Infectious Diseases</i> , 2020, 222, 1985-1996.	4.0	81
57	Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort. <i>British Journal of Haematology</i> , 2005, 128, 91-99.	2.5	80
58	Aspirin noncompliance is the major cause of aspirin resistance in patients undergoing coronary stenting. <i>American Heart Journal</i> , 2009, 157, 889-893.	2.7	78
59	Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. <i>Thrombosis Research</i> , 2007, 120, 893-899.	1.7	77
60	A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. <i>Human Molecular Genetics</i> , 2016, 25, 358-370.	2.9	73
61	Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. <i>Thrombosis Research</i> , 2009, 123, 597-603.	1.7	72
62	TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. <i>European Journal of Human Genetics</i> , 2004, 12, 1041-1049.	2.8	71
63	Germline variants in <i>ETV6</i> underlie reduced platelet formation, platelet dysfunction and increased levels of circulating CD34 <sup>+</sup> progenitors. <i>Haematologica</i> , 2017, 102, 282-294.	3.5	70
64	Prognostic value of plasma tissue factor and tissue factor pathway inhibitor for cardiovascular death in patients with coronary artery disease: the AtheroGene study. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 475-482.	3.8	68
65	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 97, 212-217.	3.4	67
66	Clinical Implications of Very Low On-Treatment Platelet Reactivity in Patients Treated With Thienopyridine. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 854-863.	2.9	67
67	The European Hematology Association Roadmap for European Hematology Research: a consensus document. <i>Haematologica</i> , 2016, 101, 115-208.	3.5	67
68	Predictive Values of Post-Treatment Adenosine Diphosphate-Induced Aggregation and Vasodilator-Stimulated Phosphoprotein Index for Stent Thrombosis After Acute Coronary Syndrome in Clopidogrel-Treated Patients. <i>American Journal of Cardiology</i> , 2009, 104, 1078-1082.	1.6	66
69	Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. <i>Thrombosis and Haemostasis</i> , 2003, 89, 554-560.	3.4	65
70	Association of Plasminogen Activator Inhibitor (PAI)-1 (SERPINE1) SNPs With Myocardial Infarction, Plasma PAI-1, and Metabolic Parameters. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2250-2257.	2.4	65
71	Effect of motivational mobile phone short message service on aspirin adherence after coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 568-569.	1.7	65
72	Multiple Biomarkers for the Prediction of Ischemic Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 659-666.	2.4	65

#	ARTICLE	IF	CITATIONS
73	A PRDX1 mutant allele causes a MMACHC secondary epimutation in cblC patients. <i>Nature Communications</i> , 2018, 9, 67.	12.8	64
74	Combined analysis of three genome-wide association studies on vWF and FVIII plasma levels. <i>BMC Medical Genetics</i> , 2011, 12, 102.	2.1	63
75	Adipose Tissue Expression of Gelatinases in Mouse Models of Obesity. <i>Thrombosis and Haemostasis</i> , 2001, 85, 1111-1116.	3.4	61
76	C4BPB/C4BPA is a new susceptibility locus for venous thrombosis with unknown protein independent mechanism: results from genome-wide association and gene expression analyses followed by case-control studies. <i>Blood</i> , 2010, 115, 4644-4650.	1.4	61
77	The insulin resistance syndrome: implications for thrombosis and cardiovascular disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002, 32, 269-273.	0.3	60
78	Effect of CYP2C19*2 and *17 Genetic Variants on Platelet Response to Clopidogrel and Prasugrel Maintenance Dose and Relation to Bleeding Complications. <i>American Journal of Cardiology</i> , 2013, 111, 985-990.	1.6	59
79	High prevalence of laminopathies among patients with metabolic syndrome. <i>Human Molecular Genetics</i> , 2011, 20, 3779-3786.	2.9	58
80	Multilocus Genetic Risk Scores for Venous Thromboembolism Risk Assessment. <i>Journal of the American Heart Association</i> , 2014, 3, e001060.	3.7	58
81	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010, 86, 592-595.	6.2	57
82	The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies. <i>Blood</i> , 2012, 119, 2392-2400.	1.4	56
83	miR-421 and miR-30c Inhibit SERPINE 1 Gene Expression in Human Endothelial Cells. <i>PLoS ONE</i> , 2012, 7, e44532.	2.5	56
84	The A $\rightarrow$ 844G Polymorphism in the PAI-1 Gene Is Associated With a Higher Risk of Venous Thrombosis in Factor V Leiden Carriers. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 1387-1391.	2.4	55
85	Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 791-797.	3.8	55
86	TAFI gene haplotypes, TAFI plasma levels and future risk of coronary heart disease: the PRIME Study. <i>Journal of Thrombosis and Haemostasis</i> , 2005, 3, 1503-1510.	3.8	55
87	Systemic chemokine levels, coronary heart disease, and ischemic stroke events. <i>Neurology</i> , 2011, 77, 1165-1173.	1.1	55
88	Genome wide association study for plasma levels of natural anticoagulant inhibitors and protein C anticoagulant pathway: the MARTHA project. <i>British Journal of Haematology</i> , 2012, 157, 230-239.	2.5	55
89	Contribution of novel biomarkers to incident stable angina and acute coronary syndrome: the PRIME Study. <i>European Heart Journal</i> , 2008, 29, 1966-1974.	2.2	53
90	Clopidogrel response: Head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting. <i>Archives of Cardiovascular Diseases</i> , 2010, 103, 39-45.	1.6	53

#	ARTICLE	IF	CITATIONS
91	KNG1 Ile581Thr and susceptibility to venous thrombosis. <i>Blood</i> , 2011, 117, 3692-3694.	1.4	53
92	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2322-2329.	3.8	52
93	Relative Contribution of Lipids and Apolipoproteins to Incident Coronary Heart Disease and Ischemic Stroke: The PRIME Study. <i>Cerebrovascular Diseases</i> , 2010, 30, 252-259.	1.7	52
94	Management of Severe Bleeding in Patients Treated with Direct Oral Anticoagulants. <i>Anesthesiology</i> , 2017, 127, 111-120.	2.5	52
95	Argatroban in the management of heparin-induced thrombocytopenia: a multicenter clinical trial. <i>Critical Care</i> , 2015, 19, 396.	5.8	49
96	Assessing the causal relationship between obesity and venous thromboembolism through a Mendelian Randomization study. <i>Human Genetics</i> , 2017, 136, 897-902.	3.8	46
97	Fat Cell Function and Fibrinolysis. <i>Hormone and Metabolic Research</i> , 2000, 32, 504-508.	1.5	45
98	Adipocytokines and the risk of coronary heart disease in healthy middle aged men: the PRIME Study. <i>International Journal of Obesity</i> , 2010, 34, 118-126.	3.4	45
99	Polymorphisms of the tumor necrosis factor-alpha (TNF) and the TNF-alpha converting enzyme (TACE/ADAM17) genes in relation to cardiovascular mortality: the AtheroGene study. <i>Journal of Molecular Medicine</i> , 2008, 86, 1153-1161.	3.9	44
100	Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: The PRIME study. <i>Atherosclerosis</i> , 2011, 218, 464-469.	0.8	43
101	Genome-Wide Association Study for Circulating Tissue Plasminogen Activator Levels and Functional Follow-Up Implicates Endothelial <i>STXB5</i> and <i>STX2</i> . <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1093-1101.	2.4	43
102	A multi-stage multi-ethnic design strategy provides strong evidence that the BAI3 locus is associated with early-onset venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2671-2679.	3.8	42
103	Current knowledge on the genetics of incident venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 111-121.	3.8	42
104	Prasugrel Monitoring and Bleeding in Real World Patients. <i>American Journal of Cardiology</i> , 2013, 111, 38-44.	1.6	41
105	Usefulness of High Clopidogrel Maintenance Dose According to CYP2C19 Genotypes in Clopidogrel Low Responders Undergoing Coronary Stenting for Non ST Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 760-765.	1.6	40
106	Role of the interferons in CD64 and CD169 expressions in whole blood: Relevance in the balance between viral or bacterial oriented immune responses. <i>Immunity, Inflammation and Disease</i> , 2020, 8, 106-123.	2.7	40
107	PDGFB, a new candidate plasma biomarker for venous thromboembolism: results from the VEREMA affinity proteomics study. <i>Blood</i> , 2016, 128, e59-e66.	1.4	39
108	Plasma Levels of Free and Total TFPI, Relationship with Cardiovascular Risk Factors and Endothelial Cell Markers. <i>Thrombosis and Haemostasis</i> , 2001, 85, 999-1003.	3.4	38

#	ARTICLE	IF	CITATIONS
109	Fine mapping of quantitative trait nucleotides underlying thrombin-activatable fibrinolysis inhibitor antigen levels by a transethnic study. <i>Blood</i> , 2006, 108, 1562-1568.	1.4	37
110	Lessons from genome-wide association studies in venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 258-264.	3.8	36
111	Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2560-2570.	2.9	36
112	Very high TAFI antigen levels are associated with a lower risk of hard coronary events: the PRIME Study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2243-2244.	3.8	35
113	Impact of Obesity and the Metabolic Syndrome on Response to Clopidogrel or Prasugrel and Bleeding Risk in Patients Treated After Coronary Stenting. <i>American Journal of Cardiology</i> , 2014, 113, 54-59.	1.6	35
114	Risk factors for venous thromboembolism in women under combined oral contraceptive. <i>Thrombosis and Haemostasis</i> , 2016, 115, 135-142.	3.4	35
115	Genome-wide association study with additional genetic and post-transcriptional analyses reveals novel regulators of plasma factor XI levels. <i>Human Molecular Genetics</i> , 2017, 26, ddw401.	2.9	35
116	Quantification of thrombin activatable fibrinolysis inhibitor (TAFI) gene polymorphism effects on plasma levels of TAFI measured with assays insensitive to isoform-dependent artefact. <i>Thrombosis and Haemostasis</i> , 2005, 94, 373-9.	3.4	34
117	Association of vitronectin and plasminogen activator inhibitor-1 levels with the risk of metabolic syndrome and type 2 diabetes mellitus. <i>Thrombosis and Haemostasis</i> , 2011, 106, 416-422.	3.4	34
118	Formyl Peptide Receptor 2 Plays a Deleterious Role During Influenza A Virus Infections. <i>Journal of Infectious Diseases</i> , 2016, 214, 237-247.	4.0	34
119	Macrothrombocytopenia and dense granule deficiency associated with FLI1 variants: ultrastructural and pathogenic features. <i>Haematologica</i> , 2017, 102, 1006-1016.	3.5	34
120	What is currently known about the genetics of venous thromboembolism at the dawn of next generation sequencing technologies. <i>British Journal of Haematology</i> , 2018, 180, 335-345.	2.5	34
121	Human thymopoiesis is influenced by a common genetic variant within the <i>TCRA-TCRD</i> locus. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	33
122	Robust validation of methylation levels association at CPT1A locus with lipid plasma levels. <i>Journal of Lipid Research</i> , 2014, 55, 1189-1191.	4.2	32
123	Blood triglyceride levels are associated with DNA methylation at the serine metabolism gene PHGDH. <i>Scientific Reports</i> , 2017, 7, 11207.	3.3	32
124	Contribution of anti-Î²2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. <i>Rheumatology</i> , 2014, 53, 1215-1218.	1.9	30
125	Fibrinolytic function and coronary risk. <i>Current Cardiology Reports</i> , 1999, 1, 119-124.	2.9	28
126	Influence of t-PA and u-PA on Adipose Tissue Development in a Murine Model of Diet-Induced Obesity. <i>Thrombosis and Haemostasis</i> , 2002, 87, 306-310.	3.4	28



#	ARTICLE	IF	CITATIONS
127	Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors. <i>Thrombosis and Haemostasis</i> , 2011, 105, 954-961.	3.4	28
128	<scp>CD169</scp> and <scp>CD64</scp> could help differentiate bacterial from <scp>CoVID</scp>â€19 or other viral infections in the Emergency Department. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 435-445.	1.5	28
129	Paraoxonase-1 and clopidogrel efficacy. <i>Nature Medicine</i> , 2011, 17, 1039-1039.	30.7	27
130	Management of cardiovascular disease in haemophilia. <i>Thrombosis Research</i> , 2013, 132, 8-14.	1.7	27
131	A meta-analysis of genome-wide association studies identifies ORM1 as a novel gene controlling thrombin generation potential. <i>Blood</i> , 2014, 123, 777-785.	1.4	27
132	Development and implementation of common data elements for venous thromboembolism research: on behalf of SSC Subcommittee on official Communication from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 297-303.	3.8	27
133	Diet Modulates Endogenous Thrombin Generation, A Biological Estimate of Thrombosis Risk, Independently of the Metabolic Status. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2394-2404.	2.4	26
134	Recent advances in the pharmacogenetics of clopidogrel. <i>Human Genetics</i> , 2012, 131, 653-664.	3.8	26
135	A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling. <i>American Journal of Human Genetics</i> , 2020, 107, 211-221.	6.2	26
136	Interaction between the C-260T polymorphism of the CD14 gene and the plasma IL-6 concentration on the risk of myocardial infarction: the HIFMECH study. <i>Atherosclerosis</i> , 2005, 179, 317-323.	0.8	25
137	A genome-wide search for common SNP x SNP interactions on the risk of venous thrombosis. <i>BMC Medical Genetics</i> , 2013, 14, 36.	2.1	25
138	Direct oral anticoagulants and digestive bleeding: therapeutic management and preventive measures. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 495-505.	3.2	25
139	Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). <i>Anaesthesia, Critical Care &amp; Pain Medicine</i> , 2018, 37, 379-389.	1.4	25
140	Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome. <i>Thrombosis Research</i> , 2010, 126, e400-e402.	1.7	24
141	Prasugrel versus ticagrelor in acute coronary syndrome: A randomized comparison. <i>International Journal of Cardiology</i> , 2013, 170, e21-e22.	1.7	24
142	ABO blood group but not haemostasis genetic polymorphisms significantly influence thrombotic risk: a study of 180 homozygotes for the Factor V Leiden mutation. <i>British Journal of Haematology</i> , 2006, 135, 697-702.	2.5	23
143	Protein Z plasma levels are not associated with the risk of coronary heart disease: the PRIME Study. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 2050-2051.	3.8	22
144	Management of antiplatelet therapy in patients undergoing elective invasive procedures: Proposals from the French Working Group on perioperative hemostasis (GIHP) and the French Study Group on thrombosis and hemostasis (GFHT). In collaboration with the French Society for Anesthesia and Intensive Care (SFAR). <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 210-223.	1.6	22

#	ARTICLE	IF	CITATIONS
145	A large-scale exome array analysis of venous thromboembolism. <i>Genetic Epidemiology</i> , 2019, 43, 449-457.	1.3	22
146	Relationship of Plasminogen Activator Inhibitor-1 Levels following Thrombolytic Therapy with rt-PA as Compared to Streptokinase and Patency of Infarct Related Coronary Artery. <i>Thrombosis and Haemostasis</i> , 1999, 82, 104-108.	3.4	22
147	Comparison of thrombotic risk between 85 homozygotes and 481 heterozygotes carriers of the factor V Leiden mutation: retrospective analysis from the Procure Study. <i>Blood Coagulation and Fibrinolysis</i> , 2000, 11, 511-518.	1.0	21
148	Thr325Ile polymorphism of the TAFI gene does not influence the risk of myocardial infarction. <i>Blood</i> , 2002, 99, 1878-1878.	1.4	21
149	The Factor XII $\alpha^2C$ Variant and Risk of Common Thrombotic Disorders: A HuGE Review and Meta-Analysis of Evidence From Observational Studies. <i>American Journal of Epidemiology</i> , 2011, 173, 136-144.	3.4	21
150	Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy. <i>International Journal of Cardiology</i> , 2013, 168, 523-528.	1.7	21
151	Anticoagulation with a new oral anticoagulant in heart transplant recipients. <i>International Journal of Cardiology</i> , 2013, 168, 4452-4453.	1.7	21
152	Body mass index has no impact on platelet inhibition induced by ticagrelor after acute coronary syndrome, conversely to prasugrel. <i>International Journal of Cardiology</i> , 2014, 176, 1200-1202.	1.7	21
153	Plasma Biomarkers and Identification of Resilient Metabolic Disruptions in Patients With Venous Thromboembolism Using a Metabolic Systems Approach. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 2527-2538.	2.4	21
154	Impact on venous thrombosis risk of newly discovered gene variants associated with FVIII and VWF plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 229-231.	3.8	20
155	Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey. <i>Surgery for Obesity and Related Diseases</i> , 2017, 13, 320-326.	1.2	20
156	Protein S inherited qualitative deficiency: novel mutations and phenotypic influence. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2718-2726.	3.8	19
157	ABO Blood Group and von Willebrand Factor Levels Partially Explained the Incomplete Penetrance of Congenital Thrombophilia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 2021-2028.	2.4	19
158	Clinical research assessment by flow cytometry of biomarkers for infectious stratification in an Emergency Department. <i>Biomarkers in Medicine</i> , 2019, 13, 1373-1386.	1.4	19
159	Association between ABO haplotypes and the risk of venous thrombosis: impact on disease risk estimation. <i>Blood</i> , 2021, 137, 2394-2402.	1.4	19
160	Comparison of Platelet Reactivity and Clopidogrel Response in Patients $\geq 75$ Years Versus $< 75$ Years Undergoing Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2011, 108, 1411-1416.	1.6	18
161	Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism. <i>Thrombosis Research</i> , 2014, 134, 426-432.	1.7	18
162	SLC44A2 deficient mice have a reduced response in stenosis but not in hypercoagulability driven venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1714-1727.	3.8	18

#	ARTICLE	IF	CITATIONS
163	Circulating Matrix Metalloproteinases in Infective Endocarditis: A Possible Marker of the Embolic Risk. <i>PLoS ONE</i> , 2011, 6, e18830.	2.5	18
164	Prothrombin G20210A carriers the genetic mutation and a history of venous thrombosis contributes to thrombin generation independently of factor II plasma levels. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 942-949.	3.8	17
165	Association of soluble endothelial protein C receptor plasma levels and PROCr rs867186 with cardiovascular risk factors and cardiovascular events in coronary artery disease patients: The Athero Gene Study. <i>BMC Medical Genetics</i> , 2012, 13, 103.	2.1	17
166	Risk assessment of venous thrombosis in families with known hereditary thrombophilia: the MARseillesâ€”Nimes prediction model. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 138-146.	3.8	17
167	Assessment of platelet function on the routine coagulation analyzer Sysmex CS-2000i. <i>Platelets</i> , 2018, 29, 95-97.	2.3	17
168	Caution in Interpreting Results from Imputation Analysis When Linkage Disequilibrium Extends over a Large Distance: A Case Study on Venous Thrombosis. <i>PLoS ONE</i> , 2012, 7, e38538.	2.5	17
169	Ala147Thr and C+1542G Polymorphisms in the TAFI Gene Are not Associated with a Higher Risk of Venous Thrombosis in FV Leiden Carriers. <i>Thrombosis and Haemostasis</i> , 2001, 86, 1583-1584.	3.4	16
170	CD11b+ leukocyte microparticles are associated with highâ€”risk angiographic lesions and recurrent cardiovascular events in acute coronary syndromes. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1870-1873.	3.8	16
171	DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis. <i>Blood</i> , 2018, 132, 1842-1850.	1.4	16
172	Impaired adhesion of neutrophils expressing Slc44a2/HNA-3b to VWF protects against NETosis under venous shear rates. <i>Blood</i> , 2021, 137, 2256-2266.	1.4	16
173	Effectiveness of switching â€”hyper respondersâ€” from Prasugrel to Clopidogrel after acute coronary syndrome: The POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study. <i>International Journal of Cardiology</i> , 2013, 168, 5004-5005.	1.7	15
174	Severe thrombophilia in a factor Vâ€”deficient patient homozygous for the Ala2086Asp mutation (FV) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	3.8	15
175	A Three-generation Family Presenting Five Cases of Homozygosity for the 20210 G to A Prothrombin Variant. <i>Thrombosis and Haemostasis</i> , 1998, 80, 859-860.	3.4	14
176	Deciphering the molecular basis of venous thromboembolism: where are we and where should we go?. <i>British Journal of Haematology</i> , 2010, 148, 495-506.	2.5	14
177	Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. <i>Scientific Reports</i> , 2017, 7, 45507.	3.3	14
178	Flow cytometry evaluation of infection-related biomarkers in febrile subjects in the emergency department. <i>Future Microbiology</i> , 2020, 15, 189-201.	2.0	14
179	Heparinâ€”induced thrombocytopenia: Construction of a pretest diagnostic score derived from the analysis of a prospective multinational database, with internal validation. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1959-1972.	3.8	14
180	Rapid Detection of Factor XIII Val34Leu by Allele Specific PCR. <i>Thrombosis and Haemostasis</i> , 1999, 81, 463-463.	3.4	13

#	ARTICLE	IF	CITATIONS
181	Relation between the antithrombin Cambridge II mutation, the risk of venous thrombosis, and the endogenous thrombin generation. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 1975-1977.	3.8	13
182	Fixed-dose aspirin+clopidogrel combination enhances compliance to aspirin after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 172, e1-e2.	1.7	13
183	Is there still room for additional common susceptibility alleles for venous thromboembolism?. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1798-1802.	3.8	12
184	Acquired Protein S Deficiency, Likely due to Anti-PS Autoantibodies, following a Thrombotic Event in a Patient with a Systemic Lupus erythematosus. <i>Thrombosis and Haemostasis</i> , 1997, 78, 1416-1417.	3.4	12
185	Multi-phenotype analyses of hemostatic traits with cardiovascular events reveal novel genetic associations. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1331-1349.	3.8	12
186	Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1910-1919.	3.8	12
187	The natural occurrence of human fibrinogen variants disrupting inter-chain disulfide bonds (A <sup>Cys36</sup> Gly, A <sup>Cys36</sup> Arg and A <sup>Cys45</sup> Tyr) confirms the role of N-terminal A <sup>A</sup> disulfide bonds in protein assembly and secretion. <i>Haematologica</i> , 2011, 96, 1226-1230.	3.5	11
188	Potential mechanism of acute stent thrombosis with bivalirudin following percutaneous coronary intervention in acute coronary syndromes. <i>International Journal of Cardiology</i> , 2016, 220, 496-500.	1.7	11
189	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020, 7, 599626.	2.6	11
190	Two <i>SERPINC1</i> variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. <i>Blood</i> , 2022, 140, 140-151.	1.4	11
191	Factor V Leiden Homozygous Genotype and Pregnancy Outcomes. <i>Obstetrics and Gynecology</i> , 2009, 114, 1249-1253.	2.4	10
192	Effectiveness of switching low responders™ to prasugrel to ticagrelor after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 176, 1184-1185.	1.7	10
193	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1 0,784314 rgBT /Over FO	1.7	10
194	Common Risk Factors Add to Inherited Thrombophilia to Predict Venous Thromboembolism Risk in Families. <i>TH Open</i> , 2019, 03, e28-e35.	1.4	10
195	ABO blood group, glycosyltransferase activity and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2020, 193, 31-35.	1.7	10
196	A novel rare c.-39C>T mutation in the PROS1 5'UTR causing PS deficiency by creating a new upstream translation initiation codon. <i>Clinical Science</i> , 2020, 134, 1181-1190.	4.3	10
197	Polymorphism A36G of the tumor necrosis factor receptor 1 gene is associated with PAI-1 levels in obese women. <i>Thrombosis and Haemostasis</i> , 2007, 97, 62-66.	3.4	10
198	Genetically defined elevated homocysteine levels do not result in widespread changes of DNA methylation in leukocytes. <i>PLoS ONE</i> , 2017, 12, e0182472.	2.5	10

#	ARTICLE	IF	CITATIONS
199	Cerebral Venous Thrombosis: Clinical, Radiological, Biological, and Etiological Characteristics of a French Prospective Cohort (FPCCVT)â€”Comparison With ISCVT Cohort. <i>Frontiers in Neurology</i> , 2021, 12, 753110.	2.4	10
200	Epimutations in both the TESK2 and MMACHC promoters in the Epi-cblC inherited disorder of intracellular metabolism of vitamin B12. <i>Clinical Epigenetics</i> , 2022, 14, 52.	4.1	10
201	Juvenile temporal arteritis and activated protein C resistance. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 215-216.	0.9	9
202	Clinical characteristics and laboratory testing of patients with suspected HIT: A survey on current practice in 11 university hospitals in France. <i>Thrombosis Research</i> , 2010, 125, e294-e299.	1.7	9
203	Genetic determinants of tissue factor pathway inhibitor plasma levels. <i>Thrombosis and Haemostasis</i> , 2015, 114, 245-257.	3.4	9
204	Bayesian network analysis of plasma microRNA sequencing data in patients with venous thrombosis. <i>European Heart Journal Supplements</i> , 2020, 22, C34-C45.	0.1	9
205	Single or triple positivity for antiphospholipid antibodies in â€œcarriersâ€”or symptomatic patients: Untangling the knot. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3018-3030.	3.8	9
206	Lipoprotein(a): Pathophysiology, measurement, indication and treatment in cardiovascular disease. A consensus statement from the Nouvelle Soci�t� Francophone d�™Ath�roscl�rose (NSFA). <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 828-847.	1.6	9
207	Long-Read Sequencing Identifies the First Retrotransposon Insertion and Resolves Structural Variants Causing Antithrombin Deficiency. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1369-1378.	3.4	9
208	Association Between Factor VII Polymorphisms and Blood Pressure. <i>Hypertension</i> , 2004, 44, 674-680.	2.7	8
209	Molecular characterization of a novel mutation in the factor XIII A subunit gene associated with a severe defect and an adulthood diagnosis. <i>Haemophilia</i> , 2007, 13, 221-222.	2.1	8
210	Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. <i>American Heart Journal</i> , 2012, 164, 327-333.	2.7	8
211	Genetic variation in F3 (tissue factor) and the risk of incident venous thrombosis: meta�analysis of eight studies. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 719-722.	3.8	8
212	No Evidence for Genome-Wide Interactions on Plasma Fibrinogen by Smoking, Alcohol Consumption and Body Mass Index: Results from Meta-Analyses of 80,607 Subjects. <i>PLoS ONE</i> , 2014, 9, e111156.	2.5	8
213	An artificial neural network approach integrating plasma proteomics and genetic data identifies PLXNA4 as a new susceptibility locus for pulmonary embolism. <i>Scientific Reports</i> , 2021, 11, 14015.	3.3	8
214	Risk of venous thromboembolism during pregnancy in homozygous carriers of the factor V Leiden mutation: are there any predictive factors?. <i>Journal of Thrombosis and Haemostasis</i> , 2004, 2, 359-360.	3.8	7
215	On the use of phylogeny�based tests to detect association between quantitative traits and haplotypes. <i>Genetic Epidemiology</i> , 2009, 33, 729-739.	1.3	7
216	Off-label use of prasugrel in stable coronary artery disease is associated with greater degree of platelet inhibition compared with use after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 2988-2989.	1.7	7

#	ARTICLE	IF	CITATIONS
217	Chronic kidney disease has a significant impact on platelet inhibition of new P2Y12 inhibitors. <i>International Journal of Cardiology</i> , 2015, 184, 428-430.	1.7	7
218	Thrombin Generation Potential and Whole-Blood DNA methylation. <i>Thrombosis Research</i> , 2015, 135, 561-564.	1.7	7
219	Genetic risk factors for venous thrombosis in women using combined oral contraceptives: update of the <scp>PILGRIM</scp> study. <i>Clinical Genetics</i> , 2017, 91, 131-136.	2.0	7
220	Lean body weight is the best scale for venous thromboprophylaxis algorithm in severely obese patients undergoing bariatric surgery. <i>Pharmacological Research</i> , 2018, 131, 211-217.	7.1	7
221	OPTIMIR, a novel algorithm for integrating available genome-wide genotype data into miRNA sequence alignment analysis. <i>Rna</i> , 2019, 25, 657-668.	3.5	7
222	Minor allele of the factor V K858R variant protects from venous thrombosis only in non-carriers of factor V Leiden mutation. <i>Scientific Reports</i> , 2019, 9, 3750.	3.3	7
223	Cell Analysis from Dried Blood Spots: New Opportunities in Immunology, Hematology, and Infectious Diseases. <i>Advanced Science</i> , 2021, 8, e2100323.	11.2	7
224	Genome-Wide Investigation of DNA Methylation Marks Associated with FV Leiden Mutation. <i>PLoS ONE</i> , 2014, 9, e108087.	2.5	7
225	Toward Monocyte HLA-DR Bedside Monitoring: A Proof-of-Concept Study. <i>Shock</i> , 2021, 55, 782-789.	2.1	7
226	Screening for Identified and Unidentified Protein C Pathway Defects by the <i>Agkistrodon contortrix</i> Venom Test in Consecutive Patients. <i>American Journal of Clinical Pathology</i> , 1999, 112, 233-237.	0.7	6
227	Factor XIIIIV34L is not an additional genetic risk factor for venous thrombosis in Factor V Leiden carriers. <i>Blood</i> , 2001, 97, 1894-1896.	1.4	6
228	Molecular characterization of a novel mutation in the factor XIII a subunit gene associated with a severe defect: importance of prophylactic substitution. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 605-606.	1.0	6
229	Prospective analysis of factor XI deficiencies in the Marseilles area identified four novel mutations among 12 consecutive unrelated families. <i>Blood Coagulation and Fibrinolysis</i> , 2009, 20, 84-88.	1.0	6
230	Homocysteine levels associate with subtle changes in leukocyte DNA methylation: an epigenome-wide analysis. <i>Epigenomics</i> , 2017, 9, 1403-1422.	2.1	6
231	A Genome Wide Association Study on plasma FV levels identified PLXDC2 as a new modifier of the coagulation process. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1808-1814.	3.8	6
232	PRDX1 gene-related epi-cblC disease is a common type of inborn error of cobalamin metabolism with mono- or bi-allelic MMACHC epimutations. <i>Clinical Epigenetics</i> , 2021, 13, 137.	4.1	6
233	GATA1 pathogenic variants disrupt MYH10 silencing during megakaryopoiesis. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2287-2301.	3.8	6
234	Polymorphisms of the lamina maturation pathway and their association with the metabolic syndrome: the DESIR prospective study. <i>Journal of Molecular Medicine</i> , 2010, 88, 193-201.	3.9	5

#	ARTICLE	IF	CITATIONS
235	Peripartum bleeding management in a patient with Cal<sc>DAG</sc>â€<sc>GEFI</sc> deficiency. <i>Haemophilia</i> , 2017, 23, e533-e535.	2.1	5
236	Clinical validation of immunoassay HemosILÂ® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 601-609.	2.1	5
237	Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0177768.	2.5	5
238	Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. <i>Thrombosis and Haemostasis</i> , 2007, 97, 212-7.	3.4	5
239	Elucidating mechanisms of genetic cross-disease associations at the PROCR vascular disease locus. <i>Nature Communications</i> , 2022, 13, 1222.	12.8	5
240	Respective contribution of conventional risk factors and antihypertensive treatment to stable angina pectoris and acute coronary syndrome as the first presentation of coronary heart disease: the PRIME Study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2009, 16, 550-555.	2.8	4
241	TFPI resistance related to inherited or acquired protein S deficiency. <i>Thrombosis Research</i> , 2012, 130, 925-928.	1.7	4
242	Impact of new P2Y12 blockers on platelet reactivity and clinical outcomes after acute coronary syndrome: Insight from a large single center registry. <i>International Journal of Cardiology Heart &amp; Vessels</i> , 2014, 4, 188-192.	0.5	4
243	Î±1-antitrypsin Pittsburgh and plasmin-mediated proteolysis. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 2023-2026.	3.8	4
244	Initial strides for invent-VTE: Towards global collaboration to accelerate clinical research in venous thromboembolism. <i>Thrombosis Research</i> , 2018, 163, 128-131.	1.7	4
245	Interest of IgG and IgM antiprothrombin autoantibodies in the exploration of antiphospholipid syndrome: a 5-year retrospective study. <i>Rheumatology</i> , 2020, 59, 1539-1544.	1.9	4
246	Explainable Artificial Neural Network for Recurrent Venous Thromboembolism Based on Plasma Proteomics. <i>Lecture Notes in Computer Science</i> , 2021, , 108-121.	1.3	4
247	The aminosterol Claramine inhibits Î²-secretase 1â€ mediated insulin receptor cleavage. <i>Journal of Biological Chemistry</i> , 2021, 297, 100818.	3.4	4
248	Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: The prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronary revascularisation). <i>Thrombosis Research</i> , 2010, 126, e397-e399.	1.7	3
249	Single nucleotide polymorphisms in an intergenic chromosome 2q region associated with tissue factor pathway inhibitor plasma levels and venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1960-1970.	3.8	3
250	Intravenous immunoglobulin in patients with acquired Von Willebrand syndrome: A single referral centre experience. <i>Haemophilia</i> , 2019, 25, e42-e45.	2.1	3
251	Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome. <i>Platelets</i> , 2019, 30, 105-111.	2.3	3
252	A Combination of Single Nucleotide Polymorphisms is Associated with the Interindividual Variability of Cholesterol Bioavailability in Healthy Adult Males. <i>Molecular Nutrition and Food Research</i> , 2020, 64, 2000480.	3.3	3

#	ARTICLE	IF	CITATIONS
253	The EHA Research Roadmap: Blood Coagulation and Hemostatic Disorders. <i>HemaSphere</i> , 2021, 5, e643.	2.7	3
254	The Assistance Publique Hôpitaux de Marseille's Biobank. <i>Open Journal of Bioresources</i> , 2020, 7, .	1.5	3
255	Catastrophic Arterial Reactivity During Primary Antiphospholipid Syndrome. <i>Angiology</i> , 1999, 50, 761-764.	1.8	2
256	Effect of increased aspirin dose after Stenting in association with Clopidogrel: The FIASCO randomized study. <i>Thrombosis Research</i> , 2009, 124, 33-36.	1.7	2
257	Lack of association of non-synonymous FUT2 and ALPL polymorphisms with venous thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 1693-1695.	3.8	2
258	Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome. <i>International Journal of Cardiology</i> , 2013, 168, 1565-1566.	1.7	2
259	High prevalence of mutations in perilipin 1 in patients with precocious acute coronary syndrome. <i>Atherosclerosis</i> , 2020, 293, 86-91.	0.8	2
260	A rare coding mutation in the MAST2 gene causes venous thrombosis in a French family with unexplained thrombophilia: The Breizh MAST2 Arg89Gln variant. <i>PLoS Genetics</i> , 2021, 17, e1009284.	3.5	2
261	Association of impaired renal function with venous thrombosis: A genetic risk score approach. <i>Thrombosis Research</i> , 2017, 158, 102-107.	1.7	2
262	Relations between hemostatic variables, insulin resistance and inflammation. <i>The Hematology Journal</i> , 2004, 5, S15-S19.	1.4	2
263	Acquired inhibitor of thrombin associated with an ulcerative colitis. <i>American Journal of Hematology</i> , 2000, 64, 322-322.	4.1	1
264	High Residual Platelet Reactivity and Thrombotic Events. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2561-2561.	7.4	1
265	Is platelet inhibition correlated with time from last intake on P2Y12 blockers after an acute coronary syndrome? A pilot study. <i>Platelets</i> , 2016, 27, 791-795.	2.3	1
266	Leveraging cell type specific regulatory regions to detect SNPs associated with tissue factor pathway inhibitor plasma levels. <i>Genetic Epidemiology</i> , 2017, 41, 455-466.	1.3	1
267	High-Dimensional Multi-Block Analysis of Factors Associated with Thrombin Generation Potential. , 2019, , .		1
268	Reply to Chen and Vitetta. <i>Journal of Infectious Diseases</i> , 2021, 223, 1660-1662.	4.0	1
269	FGL1 as a modulator of plasma D-dimer levels: Exome-wide marker analysis of plasma tPA, PAI-1, and D-dimer. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2019-2028.	3.8	1
270	Abstract 090: Slc44a2 Deficient Mice Exhibit Less Severity of Thrombosis in a Stenosis Model of Deep Vein Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, .	2.4	1



#	ARTICLE	IF	CITATIONS
271	Is Oxidative Stress an Emerging Player in the Thrombosis of Patients with Anti-Phosphatidylethanolamine Autoantibodies?. <i>Journal of Clinical Medicine</i> , 2022, 11, 1297.	2.4	1
272	Regulation of PAI-1 in obesity and insulin resistance. <i>Atherosclerosis</i> , 1999, 144, 14.	0.8	0
273	Venous thromboembolism in asymptomatic carriers of factor V Leiden mutation from symptomatic families: any role for hormonal replacement treatment?. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1325-1326.	3.8	0
274	Aprotinin Administration and Pulmonary Embolism After Aortic Valve Replacement. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2008, 22, 255-258.	1.3	0
275	Mesopic vision characteristics at decreased contrast in fog. <i>Proceedings of SPIE</i> , 2010, , .	0.8	0
276	A Follow-Up Study of a Genome-wide Association Scan Identifies a Susceptibility Locus for Venous Thrombosis on Chromosome 6p24.1. <i>American Journal of Human Genetics</i> , 2010, 86, 655.	6.2	0
277	Les facteurs de risque génétique de la thrombose veineuse: osons-nous?. <i>Sang Thrombose Vaisseaux</i> , 2010, 22, 421-427.	0.1	0
278	Effectiveness of switching hyper responders from prasugrel to clopidogrel after acute coronary syndrome: the POBA SWITCH study. <i>European Heart Journal</i> , 2013, 34, P4883-P4883.	2.2	0
279	Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (Predictor Of Bleedings with Antiplatelet drugs). <i>European Heart Journal</i> , 2013, 34, 4528-4528.	2.2	0
280	Impact of obesity on response to thienopyridine and bleeding risk in patients treated after acute coronary syndrome by clopidogrel or prasugrel. <i>European Heart Journal</i> , 2013, 34, P4878-P4878.	2.2	0
281	Economic Analysis Of Thrombo Incode, A Clinical-Genetic Function For Assessing The Risk Of Venous Thromboembolism. <i>Value in Health</i> , 2014, 17, A488.	0.3	0
282	Genetic determined low response to thienopyridines is associated with higher systemic inflammation in smokers. <i>Pharmacogenomics</i> , 2015, 16, 459-469.	1.3	0
283	The usefulness of infection biomarkers in patients with febrile neutropenia in the Emergency Department. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed )</i> , 2017, 35, 395-396.	0.3	0
284	Position du GIHP sur les tests viscoélastiques: quelle place pour quelle indication en situation hémorragique?. <i>Anesthésie &amp; Réanimation</i> , 2018, 4, 452-464.	0.1	0
285	The missing heritability of venous thrombosis: what about factor V Leiden heterogeneity?. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 2125-2127.	3.8	0
286	Ethnicity and Haemostasis: Challenge in the genomics era. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1274-1275.	3.8	0
287	Direct freezing of whole blood enables analysis of leucocyte markers by flow cytometry: a proof-of-concept study. <i>Future Microbiology</i> , 2021, 16, 955-966.	2.0	0
288	First case of a human <i>RASGRP2</i> mutation affecting Rap1 activation in platelets and causing severe bleeding.. <i>Journal of Cell Biology</i> , 2014, 206, 206101A111.	5.2	0